SCHEMBL208390

SCHEMBL208390

CC(C)C[C@H](N)C(=O)OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 3/20 0.57
RNPEP Q9H4A4 2/20 0.57
DNPEP Q9ULA0 2/20 0.57
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
SLC7A5 Q01650 1/20 0.54
LTA4H P09960 2/20 0.53
SLC15A1 P46059 1/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
SLC6A2 P23975 2/20 0.46
TAAR1 Q96RJ0 2/20 0.46
MAOA P21397 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
CYP2A6 P11509 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27802061 0.91 ANPEP (0.52) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL11338509 0.91 ANPEP (0.49) ANPEPRNPEPDNPEPALPIPKM
Tyrosine SCHEMBL11338508 0.89 SLC7A5 (0.60) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL288607 0.88 SLC7A5 (0.68) ANPEPALPIPKMPTGS1XIAP
SCHEMBL8835936 0.88 SLC7A5 (0.68) ANPEPALPIPKMPTGS1XIAP
SCHEMBL28820471 0.88 SLC7A5 (0.68) ANPEPALPIPKMPTGS1XIAP
SCHEMBL3486841 0.87 ALPI (0.58) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL29160724 0.87 SLC7A5 (0.66) ANPEPALPIPKMPTGS1XIAP
SCHEMBL302979 0.86 SLC7A5 (0.54) ANPEPRNPEPDNPEPSLC7A5SLC6A2
SCHEMBL1537215 0.86 SLC7A5 (0.54) ANPEPRNPEPDNPEPSLC7A5SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3990654-B1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED AROMATIC HYDROCARBONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-10-04 EP claimed
EP-3990654-A1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED HYDROCARBONS Covestro Intellectual Property GmbH & Co. KG (DE) 2022-05-04 EP claimed
WO-2020260119-A1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED HYDROCARBONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2020-12-30 WO claimed
US-10414815-B2 scFV antibody library ALLIGATOR BIOSCIENCE AB (SE) 2019-09-17 US claimed
CN-105367601-A Curcumin derivative and preparation method therefor UNIV SHANDONG 2016-03-02 CN claimed
US-7569208-B2 Diagnostic agents for pancreatic exocrine function TOKYO GAS COMPANY LIMITED (JP) 2009-08-04 US claimed
US-20070189966-A1 Diagnostic agents for pancreatic exocrine function TOKYO GAS COMPANY LIMITED 2007-08-16 US claimed
EP-1084137-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2001-03-21 EP claimed
WO-1999064442-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) 1999-12-16 WO claimed
EP-0932684-A2 3' GENOMIC PROMOTER REGION AND POLYMERASE GENE MUTATIONS RESPONSIBLE FOR ATTENUATION IN VIRUSES OF THE ORDER DESIGNATED MONONEGAVIRALES AMERICAN CYANAMID COMPANY (US) 1999-08-04 EP claimed
WO-1998013501-A2 3' GENOMIC PROMOTER REGION AND POLYMERASE GENE MUTATIONS RESPONSIBLE FOR ATTENUATION IN VIRUSES OF THE ORDER DESIGNATED MONONEGAVIRALES AMERICAN CYANAMID COMPANY (US) 1998-04-02 WO claimed
US-5206221-A Removal of cytotoxic lymphocytes BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1993-04-27 US claimed
CN-1068335-A C type hepatitis diagnosis preparation and vaccine LUCKY LTD (KR) 1993-01-27 CN claimed
US-5068223-A Dipeptides and derivatives used to deplete cytotoxic lymphocytes BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM 1991-11-26 US claimed
US-5047401-A Bone marrow transplants BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1991-09-10 US claimed
US-4752602-A DEACTIVATION CYTOTOXIC LYMPHOCYTES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1988-06-21 US claimed
EP-3990654-B1 MODIFIED MONOOXYGENASES FOR THE MANUFACTURE OF HYDROXYLATED AROMATIC HYDROCARBONS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-10-04 EP disclosed
US-20230212680-A1 NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF FALINI BRUNANGELO (IT) 2023-07-06 US disclosed
US-4752602-A DEACTIVATION CYTOTOXIC LYMPHOCYTES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1988-06-21 US disclosed
CN-85101907-A The manufacturing of single segment dominent human r gamma-interferon 1987-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070189966-A1 Diagnostic agents for pancreatic exocrine function AMY2A, IAPP, AMY1A ANPEP 278/4885RNPEP 252/4885DNPEP 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.